Training material for medical students Sample Clauses

Training material for medical students. The training material comprises background information and an instruction set for the HPC-based computational analysis of microbiome data using the open source software programme Qiime (xxxxx.xxx). The material has been used to successfully introduce new users (undergraduates and medical students) to high performance computing and metagenomic analyses and for teaching computational biology to postgraduate and postdoctoral researchers in the computational sciences. End-user solution type Please tick one or more Non-clinical research ✔ Clinical research Clinical decision support Drug discovery Design & optimisation In silico preclinical trials In silico clinical trials Personal health forecasting Provider: UCL/EPCC training product Contact email: x.xxxxxxxx-xxxxxxxxx@xxx.xx.xx Number of user organisations (list the top 5): UCL, PRACE Estimated users at PM0: 0 Estimated users at PM24: 150 Estimated users at PM36: 300 Access mode: Face to face training, service HPC Systems: By request Additional User Information: End user name Xxxxxx Xxxxxxxx-Xxxxxxxxx Affiliation UCL Application area Education / non-clinical research No. of associated users Medical student and undergraduate science student education; academic and industrial researcher training Target use Educational, research Improvements implemented None Impact The work has led to the education of 60 pre-clinical medical students and 180 undergraduate science students as well as the training of 60 PRACE workshop registrants; Several publications are in preparation; The work is being used to inform the UKRI business case for exascale computing Use of any e- infrastructure available via CompBioMed EPCC, SURFsara, BSC 13 Bibliography [1] X. Xxxxxxxxxx, “CompBioMed Deliverables,” [Online]. Available: xxxxx://xxx.xxxxxxxxxx.xx/media-social/publications/deliverables/. [Accessed 29 Aug 2019]. [2] X. Xxxxx, “CompBioMed D6.3 Deliverable,” [Online]. Available: xxxx://xxx.xxxxxxxxxx.xx/wp- content/uploads/2018/04/D6.3_ReportonWorkflowSystemProvision_USFD_v1.5.pdf. [Accessed 29 Aug 2019]. [3] C. Palansuriya, “CompBioMed D5.5 Deliverable,” [Online]. Available: xxxxx://xxx.xxxxxxxxxx.xx/wp-content/uploads/2019/08/CompBioMed_D5.5_Preparing- Data-Infrastructures-for-largescale-resources_V1.2.pdf. [Accessed 29 Aug 2019]. [4] X. Xxxxxxxxx, X. Xxxxxxx, X. X. Xxxxxx, X. Xxxxx, X. Xx, X. Xxxxxxxxxxxx, X. Xxxxxxx, X. Xxxxxxxxx, X. Xxxx and X. Xxxxxxxxx, “Delivering the CT2S computational workflow directly to the clinic,” in CompB...
AutoNDA by SimpleDocs

Related to Training material for medical students

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • VOLUNTEERS AND STUDENT WORKERS The Employer will utilize volunteers and student workers only to the extent they supplement and do not supplant bargaining unit employees. Volunteers and student workers will not supervise bargaining unit employees.

  • Transporting Students Teachers shall not be required to transport a student in a private vehicle on behalf of the school.

  • MATERIAL SAFETY All manufacturers, importers, suppliers, or distributors of hazardous chemicals doing business in this State must provide a copy of the current Material Safety Data Sheet (MSDS) for any hazardous chemical to their direct purchasers of that chemical.

  • Medical Information Throughout the Pupil's time as a member of the School, the School Medical Officer shall have the right to disclose confidential information about the Pupil if it is considered to be in the Pupil's own interests or necessary for the protection of other members of the School community. Such information will be given and received on a confidential, need-to-know basis.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Supplier Diversity Seller shall comply with Xxxxx’s Supplier Diversity Program in accordance with Appendix V.

  • Product Safety Seller must maintain the state of the product so that it is able to perform to its designed or intended purpose without causing unacceptable risk of harm to a person or damage to property.

  • Major Medical Program provides benefits after basic coverage is exhausted, and for medical office visits, ambulance care and durable equipment. Notes: Deductible $100 per individual, $300/family Coinsurance 80/20 Stop Loss $2,000 per individual Outpatient Psychiatric Per State Mandate

Time is Money Join Law Insider Premium to draft better contracts faster.